[{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breath Therapeutics, a Zambon Company, Initiates BOSTON-3 and BOSTON-4, Two Additional Clinical Studies for the Treatment of Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"ITALY","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A new FDA Fast Track designation for Zambon","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"ITALY","productType":"Peptide","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid\u201019 Infection in Psoriasis Patients Treated with Cyclosporin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin, Concord, Receive US FDA Approval for Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Topline Phase 1 Clinical Trial Results of OTX-CSI","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Announces U.S. FDA Filing Acceptance of NDA for Cyclosporine Topical Ophthalmic Emulsion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Newport Pharmaceuticals","sponsor":"WellSpring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wellspring Ophthalmics Announces Acquisition of Novel Cyclosporine Dry Eye Therapy Patent Portfolio from Newport Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Receives FDA Approval for Verkazia 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Completes Enrollment of Second Phase 3 Study for CyclASol\u00ae for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Completes Largest Ever Dry Eye Disease Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Launches PrCEQUA\u2122 (Cyclosporine Ophthalmic Solution 0.09% w\/v), the First Dry Eye Treatment with Nanomicellar (NCELL\u2122) technology*, in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Generic of Restasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Novaliq","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE\u00ae (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen\u2019s Verkazia\u00ae (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Harrow","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Wellspring Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellspring Ophthalmics Announces Receiving Its Second Patent for Novel Cyclosporine Dry Eye Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative Announces Termination of the Cyclosporine Treatment Arm for Critically Ill COVID-19 Patients in the I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol\u00ae for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Plans to File a Markting Authorisation Application for CyclASol\u00ae in the E.U. for the Treatment of Dry Eye Disease in July 2023","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Launches CEQUA, A Novel Therapy for Dry Eye Disease in India","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entod Pharmaceuticals Launches CYCLOTEARS Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Announces FDA Approval of Vevye (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Novaliq\u2019s Marketing Authorization Application for CyclASol\u00ae (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000435
CAPSULE;ORAL - 100MG, CAPSULE;ORAL - 25MG, CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Through a licensing agreement, Apotex will market and distribute Verkazia (cyclosporine) ophthalmic emulsion, which is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.
Cequa (cyclosporine ophthalmic solution) is a patented, novel, proprietary nanomicellar NCELL formulation of cyclosporine in a clear, preservative-free, aqueous solution. It is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
CyclASol (cyclosporine) solubilized in a novel water-free excipient, perfluorobutylpentane, it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.
Vevye (cyclosporine ophthalmic solution) is solubilized in a novel and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Cyclotears 0.05% eye drops contains cyclosporin which belongs to the group of medicines called Immunosuppressants. It is used to treat severe dry eye syndrome (keratoconjunctivitis sicca) in children and in adolescents (aged between 4-18 years).
Cequa (cyclosporine ophthalmic solution) is a calcineurin inhibitor immunosuppressant agent is now approved as a novel therapy for
dry eye disease in India.
CyclASol® consists of cyclosporine solubilized in a novel water-free excipient, perfluorobutylpentane , it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
CyclASol® (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED).
To minimize potential toxicity a relatively low oral dose of 5 mg/kg/day for a duration of 5 days was selected to be administered to patients randomized into the CSA (cyclosporine) arm.